Generic Exclusivity Triggers May Force Re-evaluation Of Brand/Generic Deals
Executive Summary
FDA's consideration of how brand/generic settlements would impact generic exclusivity may be causing firms to reconsider the arrangements
You may also be interested in...
Teva Gets Exclusivity For Generic Kytril; FDA Still Worries About Racing, Parking
In granting Teva 180-day marketing exclusivity for its generic formulation of Roche's antinausea drug Kytril (granisetron), FDA has laid out initial ground rules for determining when ANDA holders forfeit exclusivity
Teva Gets Exclusivity For Generic Kytril; FDA Still Worries About Racing, Parking
In granting Teva 180-day marketing exclusivity for its generic formulation of Roche's antinausea drug Kytril (granisetron), FDA has laid out initial ground rules for determining when ANDA holders forfeit exclusivity
Generic Exclusivity Debate Continues At FDA: What Counts As A Forfeit?
FDA is continuing its case-by-case review of the 180-day exclusivity status for ANDAs as they approach marketing - most recently for generics of Bayer's Precose (acarbose), King's Altace (ramipril) and Roche's Kytril (granisetron)